Dr. Reddy’s Laboratories (NYSE:RDY) has launched Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of Mylan’s TOBI (tobramycin) Inhalation Solution.
The TOBI brand and generic had U.S. sales of ~$97M for year ended April 2019, according to IQVIA Health.
Dr. Reddy’s Tobramycin is available in a 300 mg/5 mL, single-dose Ampule.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.